Isolere Bio

Executive Summary

Isolere Bio is a privately held biotechnology company headquartered in Durham, North Carolina, specializing in innovative bioprocessing solutions for advanced therapeutics. Founded in 2020, the company has developed the IsoTag™ Reagent Technology, a proprietary platform that combines affinity ligands with phase separation to enhance the purification of complex biologics, particularly adeno-associated viruses (AAVs) used in gene therapy. Traditional AAV purification methods suffer from low yields and purity issues, leading to high manufacturing costs and scalability challenges. Isolere's technology addresses these bottlenecks by enabling a simple, scalable, and cost-effective purification process that improves product quality and manufacturability. The platform holds promise not only for AAVs but also for other biologics such as antibodies and fusion proteins, potentially transforming downstream processing across the biopharmaceutical industry. Despite being at an early stage, Isolere Bio's technology has garnered attention for its potential to streamline production of gene therapies and other complex modalities. The company is actively seeking partnerships with gene therapy developers and contract development and manufacturing organizations (CDMOs) to commercialize its technology. If successful, Isolere could become a key enabler in the gene therapy value chain, reducing costs and accelerating time-to-market for life-saving treatments. However, the competitive landscape includes established purification technologies and emerging alternatives, and the company must demonstrate robust performance in real-world manufacturing settings.

Upcoming Catalysts (preview)

• Q2 2026Series A funding round70% success
• Q3 2026First strategic partnership with a gene therapy company or CDMO60% success
• Q4 2026Publication of preclinical data demonstrating IsoTag™ performance in AAV purification80% success